)
Visual
test
Aerovate Therapeutics
Aerovate Therapeutics (AVTE) investor relations material
Aerovate Therapeutics has been delisted
Aerovate Therapeutics Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary25 Apr, 2025
Executive summary
Halted all development of AV-101 after negative Phase 2b results; no plans to resume R&D or develop new products.
Entered into a merger agreement with Jade Biosciences; merger approved by shareholders and pending closing.
Declared a special cash dividend of $69.6 million ($2.40/share) contingent on merger closing.
Implemented a workforce reduction plan, terminating 92% of staff, incurring $6.5 million in one-time severance costs.
Company will become a holding entity for Jade's business post-merger; Aerovate shareholders will own ~1.6% of the combined company.
Financial highlights
Net loss for Q1 2025 was $2.5 million, a significant improvement from $23.2 million in Q1 2024.
No revenue generated; all product development discontinued.
Cash and cash equivalents plus short-term investments totaled $76.2 million as of March 31, 2025.
Operating expenses dropped to $3.4 million in Q1 2025 from $24.6 million in Q1 2024, reflecting the wind-down of R&D.
Net cash used in operating activities was $2.4 million in Q1 2025, down from $23.7 million in Q1 2024.
Outlook and guidance
Existing cash and investments expected to fund operations for at least 12 months while completing the merger.
No plans to resume AV-101 or initiate new product development; future operations depend on merger outcome.
If merger fails, board may pursue dissolution and liquidation, with cash available for distribution dependent on timing and liabilities.
What is the estimated cash dividend per share?
What are the risks if the merger is not completed?
What factors influenced the Exchange Ratio?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- YUM
Double-digit profit growth, digital expansion, and strategic actions defined the year. - 443060
Record 2025 revenue and profit, strong core growth, and robust 2026 outlook with high dividends. - GAIN
Record new investments and NAV growth highlight a strong quarter with robust distributions. - GAINRecord realized gains and income drove higher NAV and strong distributions in FY25.
- GAINNet investment income reached $9.1M, NAV per share was $12.99, and distributions stayed strong.
- EPAC
Directors, auditor, and executive pay were approved with strong shareholder participation. - ARCC
FY 2025 delivered $2.01 core EPS, $1.86/share net income, and a $29.5B portfolio. - GAINNAV per share rose to $13.53 on strong portfolio growth and stable adjusted NII.
- MATW
Net income $43.6M, sales $284.8M, debt reduced $174M, FY2026 EBITDA guidance $180M. - GM
Disciplined transformation, resilient cash flow, and software growth drive a strong outlook.
Aerovate Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company's lead product candidate is AV-101, a dry powder inhaled formulation of imatinib, designed to treat pulmonary arterial hypertension (PAH). This formulation aims to deliver the drug directly to the lungs, targeting the underlying disease mechanisms while minimizing systemic side effects. Aerovate Therapeutics is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage